BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World J Gastroenterol 2023; 29(17): 2571-2599 [PMID: 37213397 DOI: 10.3748/wjg.v29.i17.2571]
URL: https://www.wjgnet.com/1007-9327/full/v29/i17/2571.htm
Number Citing Articles
1
Niyaz Malayev, Samat Saparbayev, Saule Kubekova, Nurlan Zhampeissov. Actual issues of secondary prevention of liver cancer in KazakhstanJournal of Clinical Medicine of Kazakhstan 2023; 20(6): 66 doi: 10.23950/jcmk/13926
2
Jun-Tao Li, Hong-Mei Zhang, Wei Wang, Dong-Qing Wei. Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer <i>via</i> cell-cell communicationWorld Journal of Gastroenterology 2024; 30(11): 1609-1620 doi: 10.3748/wjg.v30.i11.1609
3
Qinjuan Wu, Xin Li, Menghong Long, Xianfeng Xie, Qing Liu. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinomaScientific Reports 2023; 13(1) doi: 10.1038/s41598-023-46057-4
4
Nora A. Mohamad, Tamara E. Galarza, Gabriela A. Martín. H2 antihistamines: May be useful for combination therapies in cancer?Biochemical Pharmacology 2024; 223: 116164 doi: 10.1016/j.bcp.2024.116164
5
Xinyu Gu, Shuang Li, Xiao Ma, Di Huang, Penghui Li. Heterogeneity characterization of hepatocellular carcinoma based on the sensitivity to 5-fluorouracil and development of a prognostic regression modelFrontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1252805